Clinical Trials

35 enrolled

Phase 2 Not yet recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

19 enrolled

Phase 2 Not yet recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT07007052 2025-11-26

TAGVEN

33 enrolled

Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

208 enrolled

Head & Neck

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT01340430 2024-05-09

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

43 enrolled

Pathologic Complete Response

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

65 enrolled

Phase 2 Active not recruiting

Pathologic Complete Response, Breast Neoplasms

NCT01686334 2024-03-12

WIDEA

130 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05103293 2023-12-27

PTC Guiding Neoadjuvant Treatment in Breast Cancer

86 enrolled

BreastOther neoplasm

Pathologic Complete Response, Breast Neoplasms, Pathological Conditions, Signs and Symptoms

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT05763992 2023-05-18

BREAKFAST-2

145 enrolled

Pathologic Complete Response, Breast Neoplasms, Fasting, Triple Negative Breast Neoplasms

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

90 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

69 enrolled 15 charts

Genitourinary

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

100 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04006041 2019-12-26

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

44 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT02353858 2018-02-13

HT01

78 enrolled

Hyperthermia, Pathologic Complete Response, Rectal Neoplasms

NCT01843179 2017-02-17

Sulindac for Patients With AML

Phase 2 Withdrawn

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

40 enrolled

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00636441 2015-12-11

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Phase 2 Terminated

56 enrolled 16 charts

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

60 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT01203267 2010-09-16

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

108 enrolled